New expression of PD-L1 on activated CD4+ T cells opens up new opportunities for cell interactions and signaling.
Hum Immunol
; 85(4): 110831, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38870593
ABSTRACT
Surface expression of programmed death-ligand 1 (PD-L1) is mainly observed on antigen presenting cells (APC) such as monocytes or dendritic cells (DCs). Our results showing a high expression of PD-L1 on human naïve CD4+ effector T-cells (TEFFs) and CD4+ regulatory T cells (TREGs) after activation with human DCs, allow us to propose a new role for PD-L1 and its ligands and their potential impact on new signaling pathways. Indeed, expression of PD-L1 on activated CD4+T cells could allow cis interaction with its ligands such as PD-1 and CD80, thus disrupting interactions with other signaling receptors, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or CD28, which interact with CD80. The ability to compete with hypothetical configuration modifications that may cause a change in affinity/avidity for the trans and cis interactions between these proteins expressed on T cells and/or DCs is discussed. As the study of cancer is strongly influenced by the role of the PD-L1/PD-1 pathway and CD4+T cells, new interactions, cis and/or trans, between TEFFs, TREGs and tumor cells are also proposed. The presence of PD-L1 on activated CD4+ T cells could influence the quality of the cytotoxic T lymphocyte response during priming to provide other help signals.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dendritic Cells
/
Lymphocyte Activation
/
CD4-Positive T-Lymphocytes
/
Signal Transduction
/
Cell Communication
/
B7-H1 Antigen
/
Programmed Cell Death 1 Receptor
Limits:
Humans
Language:
En
Journal:
Hum Immunol
/
Hum. immunol
/
Human immunology
Year:
2024
Document type:
Article
Country of publication: